Alios BioPharma Gains $8.4M

South San Francisco-based Alios BioPharma, which is developing small-molecule and protein-based therapeutics, said Thursday that it has raise $8.4M in a Series A funding round. The firm said the funding is the first tranche in a commitment of $24M from its investors. The round was led by Novo Venturse and Novartis Ventures, and also included Roche Venture Fund. Novo's Jack B. Nielsen will join the firm's board as Chairman along with the funding, with Campbell Murray of Novartis joining as a board member, and Carole Nuechterlein of Roche joining as an observer. More information »